ArticleAmerican journal of translational research2025
Lipid level stabilization following combination therapy with IdaGlar and Semaglutide in type 2 diabetes: a retrospective study.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy and lipid metabolism impact of intensified treatment with degludec-aspart dual insulin combined with semaglutide in patients with type 2 diabetes.
methodsA systematic comparison and analysis were conducted on the changes in glycolipid metabolism-related indicators (including fasting blood glucose, glycated hemoglobin, fructosamine, and 2-hour postprandial blood glucose), blood glucose fluctuation indicators (specifically including standard deviation of blood glucose, postprandial blood glucose fluctuation amplitude, and 24-hour average blood glucose), insulin function status indicators (serum insulin level, fasting C-peptide (FCP), and 2-hour postprandial C-peptide (2hCP)), insulin resistance index, visceral fat index, and lipid index (including total cholesterol, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol) between the two groups of patients. Additionally, the adverse reactions and their incidence rates during the treatment period were statistically analyzed.
resultsBefore treatment, there was no significant difference in glycolipid metabolism indicators, blood glucose fluctuation, insulin function and resistance index, visceral fat index, or lipid indicators between the two groups (all P > 0.05). After treatment, these indicators in both groups improved compared to before treatment, and the observation group showed significantly better outcomes than the control group (all P < 0.05). Moreover, there was no =significant difference in the incidence of adverse reactions between groups (P=0.576).
conclusionIntensified treatment with degludec-aspart dual insulin combined with semaglutide could improve blood glucose control, enhance insulin function, stabilize lipid levels, and did not increase treatment-related adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.